Inhibrx Beneish M Score

INBX -  USA Stock  

USD 38.14  1.58  4.32%

This module uses fundamental data of Inhibrx to approximate the value of its Beneish M Score. Inhibrx M Score tells investors if the company management is likely to be manipulating earnings. The score is calculated using eight financial indicators that are adjusted by a specific multiplier. Please note, the M Score is a probabilistic model and cannot detect companies that manipulate their earnings with 100% accuracy. Please see Inhibrx Piotroski F Score and Inhibrx Altman Z Score analysis.

Inhibrx Beneish M Score 

 
Refresh
Inhibrx Debt Current is fairly stable at the moment as compared to the past year. Inhibrx reported Debt Current of 1.5 Million in 2020. Debt to Equity Ratio is likely to rise to 0.98 in 2021, whereas Total Debt is likely to drop slightly above 36.8 M in 2021.
At this time, it appears that Inhibrx is an unlikely manipulator. The earnings manipulation may begin if Inhibrx's top management creates an artificial sense of financial success, forcing the stock price to be traded at a high price-earnings multiple than it should be. In general, excessive earnings management by Inhibrx executives may lead to removing some of the operating profits from subsequent periods to inflate earnings in the following periods. This way, the manipulation of Inhibrx's earnings can lead to misrepresentations of actual financial condition, taking the otherwise loyal stakeholders on to the path of questionable ethical practices and plain fraud.
-3.58
Beneish M Score - Unlikely Manipulator
Elasticity of Receivables
0.88
Asset Quality
N/A
Expense Coverage
0.98
Gross Margin Strengs
0.99
Accruals Factor
0.98
Depreciation Resistance
0.97
Net Sales Growth
1.05
Financial Leverage Condition
0.89

Inhibrx Beneish M-Score Indicator Trends

The cure to earnings manipulation is the transparency of financial reporting. It will typically remove the temptation of the top executives to inflate earnings (i.e., to promote the idea of 'winning at any cost'). Because a healthy internal audit department can enhance transparency, the board should promote the auditors' access to all the record-keeping systems across the enterprise. For example, if Inhibrx's auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back.
Current ValueLast YearChange From Last Year 10 Year Trend
Revenues13.5 M12.9 M
Sufficiently Up
Increasing
Slightly volatile
Selling General and Administrative ExpenseM6.8 M
Fairly Up
Increasing
Slightly volatile
Depreciation Amortization and Accretion2.3 M2.4 M
Fairly Down
Increasing
Slightly volatile
Total Assets155.1 M143.7 M
Significantly Up
Increasing
Slightly volatile
Property Plant and Equipment Net10.7 M11.3 M
Notably Down
Increasing
Slightly volatile
Trade and Non Trade Receivables568.3 K615 K
Significantly Down
Decreasing
Slightly volatile
Total Liabilities64.7 M68.3 M
Notably Down
Increasing
Slightly volatile
Current Assets142.6 M132.2 M
Significantly Up
Increasing
Slightly volatile
Assets Non Current11.3 M11.6 M
Fairly Down
Increasing
Slightly volatile
Current Liabilities29.7 M31.4 M
Notably Down
Increasing
Slightly volatile
Liabilities Non Current35 M36.9 M
Notably Down
Increasing
Slightly volatile
Total Debt36.8 M37.5 M
Fairly Down
Increasing
Slightly volatile
Debt Current1.5 M1.5 M
Fairly Up
Decreasing
Slightly volatile
Debt Non Current33.7 M36 M
Notably Down
Increasing
Slightly volatile
Gross Margin0.890.9
Fairly Down
Decreasing
Slightly volatile

Inhibrx Beneish M-Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to detect the potential manipulation of earnings. Understanding the correlation between Inhibrx's different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Inhibrx in a much-optimized way. Analyzing correlations between earnings drivers directly associated with dollar figures is the most effective way to find Inhibrx's degree of accounting gimmicks and manipulations.

About Inhibrx Beneish M Score

M-Score is one of many grading techniques for value stocks. It was developed by Professor M. Daniel Beneish of the Kelley School of Business at Indiana University and published in 1999 under the paper titled The Detection of Earnings Manipulation. The Beneish score is a multi-factor model that utilizes financial identifiers to compile eight variables used to classify whether a company has manipulated its reported earnings. The variables are built from the officially filed financial statements to create a final score call 'M Score.' The score helps to identify companies that are likely to manipulate their profits if they show deteriorating gross margins, operating expenses, and leverage against growing revenue.

Depreciation Amortization and Accretion

2.34 MillionShare
Inhibrx Depreciation Amortization and Accretion is fairly stable at the moment as compared to the past year. Inhibrx reported Depreciation Amortization and Accretion of 2.39 Million in 2020

About Inhibrx Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Inhibrx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inhibrx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inhibrx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. Inhibrx, Inc. was founded in 2010 and is headquartered in La Jolla, California. Inhibrx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 84 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Inhibrx without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Financial Widgets Now

   

Financial Widgets

Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Inhibrx using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Inhibrx Piotroski F Score and Inhibrx Altman Z Score analysis. Note that the Inhibrx information on this page should be used as a complementary analysis to other Inhibrx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.

Complementary Tools for Inhibrx Stock analysis

When running Inhibrx price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
ETF Directory
Find actively traded Exchange Traded Funds (ETF) from around the world
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
The market value of Inhibrx is measured differently than its book value, which is the value of Inhibrx that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibrx's value that differs from its market value or its book value, called intrinsic value, which is Inhibrx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibrx's market value can be influenced by many factors that don't directly affect Inhibrx underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibrx's value and its price as these two are different measures arrived at by different means. Investors typically determine Inhibrx value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibrx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.